Edgar Filing: PURE BIOSCIENCE - Form 4

PURE BIOSO Form 4	CIENCE									
April 11, 200	8									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMM Washington, D.C. 20549						COMMISSION		PPROVAL 3235-0287		
if no long subject to Section 10 Form 4 or Form 5 obligation	er STATEM	uant to Section	T OF CHANGES IN BENEFICIAL OWNE SECURITIES t to Section 16(a) of the Securities Exchange A					Expires: Estimated a burden hou response	rs per	
may conti See Instru 1(b).	nue. Section 17(a) of the Public 1 30(h) of the 1	•	U .			f 1935 or Sectio 40	n		
(Print or Type R	esponses)									
Thompson Tommy G Syr			2. Issuer Name and Ticker or Trading ymbol YURE BIOSCIENCE [PURE]				5. Relationship of Reporting Person(s) to Issuer			
(M			3. Date of Earliest Transaction (Month/Day/Year) 04/09/2008				(Check all applicable) <u>X</u> Director Officer (give title 10% Owner below) Other (specify below)			
	nendment, Da onth/Day/Year	ndment, Date Original th/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
ALEXANDI	RIA, VA 22304						Person		porting	
(City)	(State) (2	Zip) Ta	ble I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, any (Month/Day/Year)		Code	Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5) (A)		of	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock (1)	04/09/2008		Code V A	Amount 30,000	or (D) A	Price \$ 5.7	(Instr. 3 and 4) 211,100	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: PURE BIOSCIENCE - Form 4

1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	4. 5. TransactionNumber Code of (Instr. 8) Derivati Securitie Acquiree (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year) vative urities uired or posed D) tr. 3,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr	
		Code V	<i>.</i>	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
I. S.	Director	10% Owner	Officer	Other			
Thompson Tommy G 264 MEDLOCK LANE ALEXANDRIA, VA 22304	Х						
Signatures							

/s/ Dennis Brovarone Attorney-in-fact for Tommy G. Thompson

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Granted pursuant to Pure Bioscience 2007 Equity Compensation Plan

Remarks:

There are no other changes to previously reported derivative securities

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

2

04/11/2008

Date